Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005404 | 0.83 | PSMB8 (0.56) | GRM5KDM4EALDH1A1HPGD | |
| 4-Acetyl-2-Benzoxazolinone SCHEMBL3546681 | 0.82 | GRM5 (0.64) | GRM5EPHX2KDM4E | |
| SCHEMBL15295603 | 0.82 | PIM1 (0.48) | GRM5CREBBPKDM4EALDH1A1HPGD | |
| SCHEMBL2482363 | 0.80 | GRM5 (0.66) | GRM5EPHX2 | |
| SCHEMBL1005732 | 0.79 | GRM5 (0.64) | GRM5EPHX2 | |
| Lithium Ion SCHEMBL1005730 | 0.78 | GRM5 (0.58) | GRM5EPHX2 | |
| SCHEMBL16174269 | 0.75 | CREBBP (0.49) | CREBBPKDM4EALDH1A1HPGD | |
| SCHEMBL2149816 | 0.73 | PSMB8 (0.65) | GRM5EPHX2KDM4EALDH1A1HPGD | |
| SCHEMBL4504381 | 0.73 | CREBBP (0.47) | CREBBPKDM4EALDH1A1HPGD | |
| SCHEMBL15567238 | 0.73 | KDM4E (0.43) | GRM5EPHX2CREBBPKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2320906-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | BETA PHARMA CANADA INC (CA) | 2016-02-24 | — | — | EP | disclosed |
| US-8404736-B2 | Heterocyclic amide derivatives as EP4 receptor antagonists | BETA PHARMA CANADA INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8404736-B2 | Heterocyclic amide derivatives as EP4 receptor antagonists | BETA PHARMA CANADA INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | BETA PHARMA CANADA INC. (CA) | 2011-06-09 | — | — | US | disclosed |
| US-7863271-B2 | 2-aminobenzoxazole carboxamides as 5HT3 modulators | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| WO-2010019796-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | CHEMIETEK, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-2061460-A2 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | Albany Molecular Research, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080255114-A1 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | AMR TECHNOLOGY, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008019372-A2 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255114-A1 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | HTR3E, HTR3C, HTR3A | GRM5 237/4885EPHX2 3170/4885CREBBP 2196/4885 |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | PTGER4, PTGER1, PTGER2 | GRM5 429/4885EPHX2 126/4885CREBBP 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.